


ERIC BRAVIN, MD

242 Towers Road Milford NY 13807
Home phone 607-547-5003 (preferred)
Cell phone 607-376-2398
Email OncExpert@proton.me



Summary of Expertise:

22 years practicing medical oncology with current active board certification.
21 years cancer clinical trials and research experience, with leadership role at Bassett Healthcare Cancer Treatment Center.
Honored for excellence in teaching residents and medical students.
Licensed to practice medicine in NY State with active DEA license.

Current Positions:

July 2001 - Present	Attending Physician, Hematology/Oncology Bassett Cancer Institute, Bassett Healthcare Network Cooperstown, NY
2002 - Present	Director, Clinical Research Bassett Cancer Institute, Bassett Healthcare Network Cooperstown, NY

Current Licensure and Certification:

1996 - Present	State of New York, Medicine
1998	American Board of Internal Medicine
2001	American Board of Internal Medicine, Medical Oncology
2008	Recertification-American Board of Internal Medicine, Internal Medicine (No longer active).
2011	Recertification-American Board of Internal Medicine, Medical Oncology
2022	Recertification-American Board of Internal Medicine, Medical Oncology
Present	Active DEA license.

Current Research Certifications:

CITI Program Biomedical Research
CITI Program GCP for Clinical Trials Involving Drugs
CITI Program GCP for Clinical Trials with Investigational Drugs and Biologics
CIT Program GCP for Clinical Investigations of Devices

Professional Affiliations:

American Society of Clinical Oncology

Education and Training:

1998 - 2001 Hematology/Medical Oncology Fellowship
Roswell Park Cancer Institute
SUNY Buffalo School of Medicine and Biomedical Sciences
Buffalo, NY

1997 - 1998 Medicine, Chief Residency
The Mary Imogene Bassett Hospital
Cooperstown, NY

1994 - 1997 Primary Care Medicine Residency
The Mary Imogene Bassett Hospital
Cooperstown, NY

May 1994 M.D., Albany Medical College
Albany, NY

May 1992 B.S., Biology, cum laude, Rensselaer Polytechnic Institute
Troy, NY

Academic Appointments:

April 2009 Clinical Assistant Professor of Medicine
Albany Medical College
Albany, NY

2001 Instructor in Clinical Medicine
Columbia University, College of Physicians and Surgeons

Honors:

2016 Golden Apple Award for resident teaching.

1998 E. Donnell Thomas Outstanding Research Presentation Award

1993 Schaffer Prize for Excellence in Pathology, Albany Medical College

1992 Junior Alpha Omega Alpha, Albany Medical College

1992 Sandoz Award for Excellence in Neuroscience, Albany Medical College

1992 Dean's Award - Honorable Mention in Research

Research:

NCT Number	Study Title
NCT04245683	1526939: Feasibility of Non-Operative Management of Rectal Cancer in a Rural Population
NCT03851445	LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

NCT0337749 1	PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma
NCT0372392 8	S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usua; Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
NCT0127433 8	E1609: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon a-2b for Resected High-Risk Melanoma
NCT0182483 6	E1Z11: A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
NCT0043351 1	E5103: A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer
NCT0021773 7	E5202: A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers
NCT0127567 7	NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
NCT0251339 4	PALLAS: PALbociclib CoLLaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
NCT0112024 9	S0931: EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
NCT0031018 0	The TAILORx Trial- Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment
NCT0299373 1	CanStem111P: A Phase III Study of BBI-608 Plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma
NCT0124280 0	E2108: A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
NCT0110762 6	E5508: Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

Publications:

James Wang, Kyle A. Udd, Aleksandra Vidisheva, Regina A. Swift, Tanya M. Spektor, **Eric Bravin**, Emad Ibrahim, Jonathan Treisman, Mohammed Masri, James R. Berenson. Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy. Supportive Care in Cancer, 23 February, 2016

Nischala Ammannagari, Shailaja Chikoti and **Eric Bravin**. Hodgkin's lymphoma presenting as a complex paraneoplastic neurological syndrome: a case report. *Journal of Medical Case Reports* 2013 7:96.

J R Berenson, O Yellin, T Kazamel, J D Hilger, C-S Chen, A Cartmell, T Woliver, M Flam, **E Bravin**, Y Nassir, R Vescio and R A Swift. A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma. *Leukemia* (2012) 26, 1675–1680; doi:10.1038/leu.2012.51

Panneerselvam, N., Engle, A., Beechy, C., Jastremski, C., Gunasekaran, K., & **Bravin, E.** (2016, May 2). PCA For Refractory Dyspnea: Old Technology, Novel Stragety. *American Journal of Respiratory Critical Care Medicine*, A3446.

Bethuel NW, **Bravin E**, Krupa N, Jenkins P, Scribani M, Gadomski A. Bone marrow biopsy and aspiration: a departmental financial comparison in a rural hospital. *BMC Res Notes*. 2021 Mar 4;14(1):84. doi: 10.1186/s13104-021-05491-1. PMID: 33663562; PMCID: PMC7934260.

Presentations:

Saleen,S., Shahnawaz, A., Patel, A., **Bravin, E.**, (American College of Gastroenterology October 2016) Poster Presentation, Mantle Cell Lymphoma Mimicking Crohn's Disease.

Idrees, M., Zaidi, J., Bravin,E., (Miami Breast Cancer Conference March 2018) Poster Presentation, Spontaneous Tumor Lysis Syndrome; A Rare Presentation in Breast Cancer.